INTRODUCTION
Multiple myeloma, malignancy, hematological malignant diseases, MM
MULTIPLE MYELOMA
Multiple myeloma (MM) is a B‐cell malignancy accounting for 10% of hematological malignant diseases worldwide, with about 120,000 new cases every yearThe feasibility of re‐treating MM patients with single‐agent bortezomib (BTZ) was first confirmed in the phase III VISTA trial,Plitidepsin is a cyclic depsipeptide originally extracted from the tunicate In vitro, synergistic activity was found for the combination of plitidepsin with BTZ or DXM in MM cell lines and primary MM cells.The objective of this phase I clinical trial was to determine the recommended dose (RD) for phase II studies, the activity and safety profile, and the pharmacokinetics (PK) of plitidepsin in combination with BTZ and DXM in patients with r/r MM.